Sacubitril/valsartan research in chronic kidney disease from 2013 to 2025 demonstrated sustained growth in cardiorenal applications, while identifying gaps in long-term safety and dialysis dosing.
This bibliometric analysis maps the evolving research landscape of sacubitril/valsartan in CKD, highlighting a shift towards cardiorenal applications and identifying areas needing further study.
This bibliometric analysis delineates the evolving research landscape of sacubitril/valsartan in CKD from 2013 to 2025, highlighting sustained growth, key contributors, and emerging research themes. The findings underscore increasing attention to cardiorenal applications, precision medicine, and combination therapies, while also identifying persistent gaps related to long-term safety, dialysis dosing, and renoprotective mechanisms. These insights provide a structured reference to inform future clinical and translational research in CKD.
Liu et al. (Tue,) conducted a other in Chronic kidney disease. Sacubitril/valsartan was evaluated. Sacubitril/valsartan research in chronic kidney disease from 2013 to 2025 demonstrated sustained growth in cardiorenal applications, while identifying gaps in long-term safety and dialysis dosing.